Navigation Links
Biocon to colloborate for development of Oral peptide drugs for heart diseases.

The Indian Biotech Company, Biocon to colloborate with Nobex Corporation of United States to develop a new oral peptide drug for cardiovascular diseases. The spokesperson of Biocon informed that the company has gone into global research collaboration // on Tuesday for development of peptide based product for treatment of cardiovasculoar diseases. The Biocon press release said, “The collaboration combines the peptide production capabilities of Biocon with the proprietary oral peptide deliver technology of Nobex. Biocon and Nobex plan to advance the oral human brain type natriuretic peptide (hBNP) program towards an Investigational New drug filing with the US food and Drug Administration in 2007 and clinical trials beginning later that year.

“Administration of hBNP by continuous infusion was approved by the FDA in August 200 for the treatment of acute congestive heart failure in the hospital care setting. The intent of an oral hBNP would be to have a product available for chronic use, rather than only for acute use for a number of potential indications, including early stage heart failure patients.’ It said.

“By co-developing a therapeutic product such a oral hBNP of substantial clinical and market value in treating heart failure and other potential cardiovascular indications, we are taking another step towards our innovative product development strategy,” the release quoted Ms Kiran Mazumdar-Shaw, chairman and managing director of Biocon, as sayin.
'"/>




Page: 1

Related medicine news :

1. Biocon To Raise Its Investment In Scotland
2. Biocon To Shift Focus On Innovation To Accelerate Growth
3. Kalam Dedicates New Cancer Drug Developed By Biocon
4. Bayer to Market Biocon Insulin in China
5. Biocon Launches Anti-Cancer Drug
6. Biocon to Launch Anti-arthritis Drug
7. Biocon Unveils Renal Therapies for Kidney Disorders
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Cancer drugs in development nearly doubled since 1995
10. Role of zinc in development
11. Particulate matter affects lung development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... NC (PRWEB) , ... August 17, 2017 , ... ... dental practice, is adding a new location in Goldsboro, NC to its family ... care that is Riccobene Associates’ trademark starting August 15, 2017. , Riccobene ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... series, proudly announces that it will feature the National Council for Therapeutic Recreation ... for more information. , Established in 1981, NCTRC is a non-profit, international organization ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
(Date:8/17/2017)... GA (PRWEB) , ... August 17, 2017 , ... ... to welcome Dr. Kristi Hebert to its newest location in East ... enthusiastic to have Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for ... kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: